AbbVie Inc. (NYSE:ABBV) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of AbbVie Inc. (NYSE:ABBV - Get Free Report) have been given an average rating of "Moderate Buy" by the twenty-seven analysts that are presently covering the stock, Marketbeat.com reports. Eight equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $211.29.

A number of research firms recently commented on ABBV. The Goldman Sachs Group reiterated a "neutral" rating and issued a $194.00 target price on shares of AbbVie in a research report on Tuesday, April 8th. Erste Group Bank upgraded AbbVie to a "strong-buy" rating in a research report on Monday, March 17th. BNP Paribas upgraded AbbVie to a "hold" rating in a research report on Thursday, May 8th. Guggenheim boosted their target price on AbbVie from $214.00 to $216.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. Finally, Bank of America boosted their target price on AbbVie to $204.00 and gave the stock a "hold" rating in a research report on Monday, June 9th.

AbbVie Stock Performance

NYSE ABBV opened at $189.50 on Friday. The firm has a market cap of $334.73 billion, a price-to-earnings ratio of 80.64, a price-to-earnings-growth ratio of 1.26 and a beta of 0.48. The company has a quick ratio of 0.64, a current ratio of 0.76 and a debt-to-equity ratio of 44.14. The business has a 50-day moving average price of $187.37 and a 200-day moving average price of $188.56. AbbVie has a twelve month low of $163.81 and a twelve month high of $218.66.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings data on Friday, April 25th. The company reported $2.46 earnings per share for the quarter, topping analysts' consensus estimates of $2.40 by $0.06. The firm had revenue of $13.34 billion during the quarter, compared to analyst estimates of $12.91 billion. AbbVie had a return on equity of 412.03% and a net margin of 7.31%. The business's quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.31 earnings per share. As a group, equities research analysts predict that AbbVie will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 15th. Investors of record on Tuesday, July 15th will be paid a $1.64 dividend. The ex-dividend date is Tuesday, July 15th. This represents a $6.56 annualized dividend and a yield of 3.46%. AbbVie's dividend payout ratio (DPR) is currently 279.15%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. TD Capital Management LLC boosted its position in AbbVie by 82.9% during the 1st quarter. TD Capital Management LLC now owns 128 shares of the company's stock valued at $27,000 after acquiring an additional 58 shares in the last quarter. Abound Financial LLC bought a new stake in AbbVie during the 1st quarter valued at $30,000. EnRich Financial Partners LLC boosted its position in AbbVie by 196.4% during the 4th quarter. EnRich Financial Partners LLC now owns 166 shares of the company's stock valued at $29,000 after acquiring an additional 110 shares in the last quarter. Cypress Capital Management LLC WY bought a new stake in AbbVie during the 1st quarter valued at $35,000. Finally, Prudent Man Investment Management Inc. bought a new stake in AbbVie during the 4th quarter valued at $32,000. Institutional investors own 70.23% of the company's stock.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.